Your browser doesn't support javascript.
loading
Safety and feasibility of oesophageal ultrasound for the work-up of thoracic malignancy in patients with respiratory impairment.
Christiansen, Ida Skovgaard; Bodtger, Uffe; Nessar, Rafi; Salih, Goran Nadir; Kolekar, Shailesh; Sidhu, Jatinder Sing; Høegholm, Asbjørn; Laursen, Christian B; Arshad, Arman; Clementsen, Paul Frost.
Afiliação
  • Christiansen IS; Respiratory Research Unit (PLUZ), Department of Respiratory Medicine, Zealand University Hospital, Næstved, Denmark.
  • Bodtger U; Department of Internal Medicine, Zealand University Hospital, Roskilde, Denmark.
  • Nessar R; Respiratory Research Unit (PLUZ), Department of Respiratory Medicine, Zealand University Hospital, Næstved, Denmark.
  • Salih GN; Department of Internal Medicine, Zealand University Hospital, Roskilde, Denmark.
  • Kolekar S; Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.
  • Sidhu JS; Department of Internal Medicine, Zealand University Hospital, Roskilde, Denmark.
  • Høegholm A; Department of Internal Medicine, Zealand University Hospital, Roskilde, Denmark.
  • Laursen CB; Department of Internal Medicine, Zealand University Hospital, Roskilde, Denmark.
  • Arshad A; Respiratory Research Unit (PLUZ), Department of Respiratory Medicine, Zealand University Hospital, Næstved, Denmark.
  • Clementsen PF; Department of Internal Medicine, Zealand University Hospital, Roskilde, Denmark.
J Thorac Dis ; 15(7): 3965-3973, 2023 Jul 31.
Article em En | MEDLINE | ID: mdl-37559642
ABSTRACT
Biopsying lung tumours with endobronchial access in patients with respiratory impairment is challenging. However, fine needle aspiration with the endobronchial ultrasound-endoscope via the oesophagus (EUS-B-FNA) makes it possible to obtain tissue samples without entering the airways. Safety of EUS-B-FNA in these patients has not earlier been investigated prospectively. Therefore, this study aimed at assessing feasibility and safety of EUS-B-FNA from centrally located tumours suspected of thoracic malignancy in patients with respiratory insufficiency. The study is a prospective observational study. Patients with indication of EUS-B-FNA of centrally located tumours and respiratory impairment defined as modified Medical Research Council (mMRC) dyspnoea scale score of ≥3, saturation ≤90% or need of continuous oxygen supply were included prospectively in three centres. Any adverse events (AEs) were recorded during procedure and 1-hour recovery. AEs were defined as hypoxemia (saturation <90% or need for increased oxygen supply) or any kind of events needing intervention. Late procedure-related events were recorded during 30-day follow-up. Between April 1, 2020 and January 30, 2021, 16 patients were included. No severe AEs (SAEs) occurred, but AEs were seen in 50% (n=8) and 13% (n=2) of the patients during procedure and recovery respectively. AEs included hypoxemia corrected with increased oxygen supply and in two cases reversal of sedation. Late procedure-related events were seen in 13% (n=2) and included prolonged need of oxygen and one infection treated with oral antibiotics. In this cohort, EUS-B-FNA of centrally located tumours was safe and feasible in patients with respiratory impairment, when examined in the bronchoscopy suite. A variety of mostly mild and manageable complications may occur, a few even up to 30 days post-procedure.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article